Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and in vivo

• Published in: Journal of cellular and molecular medicine Vol. 23; no. 3; pp. 1951 - 1962
• Main Authors: Li, Qinghua, Ding, Youcheng, Guo, Xinlai, Luo, Shenggen, Zhuang, Huiren, Zhou, JingE, Xu, Nan, Yan, Zhiqiang
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.03.2019; John Wiley and Sons Inc
• Subjects: 3T3 Cells; Animals; Apoptosis; Apoptosis - drug effects; Cell Line; Cell Membrane - drug effects; Cell membranes; Cytoplasm; Drug Carriers - chemistry; Fibrosis; hepatic fibrosis; Hepatic Stellate Cells - drug effects; Hepatic Stellate Cells - metabolism; Hepatocytes; Humans; liposome; Liposomes; Liposomes - chemistry; Liver; Liver cirrhosis; Liver Cirrhosis - drug therapy; Liver Cirrhosis - metabolism; Mice; Nanoparticles; Nanoparticles - chemistry; Original; Rodents; Stellate cells; targeting therapy; TNF-Related Apoptosis-Inducing Ligand - metabolism; TRAIL; TRAIL protein; Nanoparticles; TRAIL; targeting therapy; hepatic fibrosis; liposome; liver cirrhosis

At present, no satisfactory anti‐liver fibrosis drugs have been used clinically due to the poor targeting ability and short half‐life period. This study aimed to explore the effects of a new TRAIL (TNF‐related apoptosis‐inducing ligand) preparation that can target aHSCs (activated hepatic stellate c...